NASDAQ: BCAXBicara Therapeutics Inc Stock
$21.69+0.41 (+1.93%)
Updated Jun 12, 2026
BCAX Price
$21.69
Fair Value Price
$1.74
Market Cap
$1.43B
52 Week Low
$8.48
52 Week High
$24.25
P/E
-7.8x
P/B
2.77x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$157.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$116M
Beta
1.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BCAX Overview
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BCAX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BCAX
Ranked#292 of 463
Ranked#292 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important BCAX news, forecast changes, insider trades & much more!
BCAX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BCAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCAX ($21.69) is overvalued by 1,148.69% relative to our estimate of its Fair Value price of $1.74 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCAX ($21.69) is not significantly undervalued (1,148.69%) relative to our estimate of its Fair Value price of $1.74 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCAX due diligence checks available for Premium users.
Valuation
BCAX fair value
Fair Value of BCAX stock based on Discounted Cash Flow (DCF)
Price
$21.69
Fair Value
$1.74
Overvalued by
1,148.69%
BCAX ($21.69) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCAX ($21.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.8x
Industry
16.53x
Market
14.15x
BCAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.77x
Industry
4.85x
BCAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BCAX's financial health
Profit margin
Revenue
$0.0
Net Income
-$56.2M
Profit Margin
0%
BCAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$553.6M
Liabilities
$39.6M
Debt to equity
0.08
BCAX's short-term assets ($544.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCAX's short-term assets ($544.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$37.5M
Investing
$100.9M
Financing
$163.3M
BCAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCAX vs Biotech Stocks
Bicara Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.